Trial record 1 of 2 for:
IROCAS
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (IROCAS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02967289 |
|
Recruitment Status :
Recruiting
First Posted : November 18, 2016
Last Update Posted : August 3, 2022
|
Sponsor:
UNICANCER
Collaborators:
Canadian Cancer Trials Group
GONO GROUP
Information provided by (Responsible Party):
UNICANCER
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The trial is a phase III, multicenter, open-labeled randomized trial comparing the association 5-fluorouracil (5-FU), folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, 5-FU (mFOLFOX 6) chemotherapy protocols in patients with high-risk stage III colon cancer in the adjuvant setting.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) | Drug: Irinotecan Drug: Folfox Protocol | Phase 3 |
After inclusion and non-inclusion criteria have been fulfilled and the patient consent has been obtained, the patient will be included and randomized in the trial. The maximum delay allowed between the signature of the consent form by the patient and the randomization in the study is 28 days.
The randomization procedure using minimization method will allocate the treatments mFOLFIRINOX or mFOLFOX 6 with a 1:1 ratio, and will be stratified by the following criteria:
- Perforation or urgent surgery versus no perforation and no urgent surgery.
- T1-T3N2 vs T4aN1 versus T4bN1 versus T4N2.
- Right colon (right of splenic flexure) vs left colon.
- Country (France vs Canada vs Italy). Patient eligible and who have signed the informed consent will be randomized in one of the two treatments arms and will receive every 14 days their treatment for a duration of 12 cycles.
Arm A: mFOLFIRINOX Arm B: mFOLFOX 6
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 792 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting |
| Actual Study Start Date : | March 27, 2017 |
| Estimated Primary Completion Date : | June 2024 |
| Estimated Study Completion Date : | June 2027 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm A
mFOLFIRINOX Folfox Protocol + Irinotecan
|
Drug: Irinotecan
every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
Other Name: Campto Drug: Folfox Protocol every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
Other Name: acid folinic + oxaliplatine + 5-FU |
|
Active Comparator: Arm B
mFOLFOX 6 Folfox Protocol
|
Drug: Folfox Protocol
every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
Other Name: acid folinic + oxaliplatine + 5-FU |
Primary Outcome Measures :
- Disease Free Survival (DFS) [ Time Frame: 3 YEARS after inclusion ]
DFS :
defined as the time from the date of randomization up to the date of:
- first local, regional or distant relapse;
- second colorectal cancer;
- death from any cause included treatment-related death.
Secondary Outcome Measures :
- Disease Free Survival [ Time Frame: 2 YEARS after inclusion ]
DFS :
defined as the time from the date of randomization up to the date of:
- first local, regional or distant relapse;
- second colorectal cancer;
- death from any cause included treatment-related death.
- Overall Survival [ Time Frame: 5 YEARS after inclusion ]Overall Survival (OS) is defined as the time from the date of randomization to the date of documented death from any cause
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 2 YEARS after inclusion ]
Safety of the study treatment will be assessed on occurrence of Adverse Events (AEs), intake of concomitant treatments, per-treatment arising changes in physical examination, vital signs (blood pressure, pulse rate and body temperature), ECG, and clinical laboratory tests (biochemistry, haematology). Safety parameters will be graded based on NCI CTCAE v4.03 classification.
The following parameters will be particularly followed:
The incidence of haematological toxicities (grade 3-4, in particular neutropenia and febrile neutropenia); The incidence of GI toxicities, in particular diarrhea; The incidence of peripheral neuropathy.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
DIAGNOSIS AND INCLUSION CRITERIA:
- Patient ≥18 years and < 75 years
- Patient ≥18 years and <71 years must have an ECOG ≤1 - Patients ≥71 years and < 75 years must have an ECOG = 0
- Pathologically confirmed high-risk stage III colon adenocarcinoma, restricted to pT4N1 or pT1-4N2 tumor.
- Curative R0 surgical resection.
- Patients who have undergone surgery for colon cancer, defined as a tumor location >12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery (high rectum), without gross or microscopic evidence of residual disease after surgery with curative intent
- Start of study drug treatment has to be performed less than 56 days after surgery.
- No prior chemotherapy.
- No prior abdominal or pelvic irradiation.
-
Patient with adequate organ function:
- Absolute neutrophil count (ANC) ≥ 2 x 109/L
- Haemoglobin ≥9 g/dL
- Platelets (PTL) ≥100 x 109/L
- AST/ALT ≤2.5 x ULN
- Alkaline phosphatase ≤2.5 x ULN
- Total Bilirubin ≤1.5 x ULN (Upper Limit of Normal)
- Creatinine clearance ≥50 mL/min (Cockcroft and Gault formula)
- Kalemia, magnesemia, calcemia ≥ 1 LLN (Lower Limit of Normal)
- Carcinoembryogenic antigen (CEA) ≤10ng/mL after surgery (during screening period)
- Adequate contraception if applicable.
- Patient able and willing to comply with study procedures as per protocol
- Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures
- Public or private health insurance coverage
- Life expectancy of > or = at 5 years
- Uracilemia < 16 ng/ml (only for french centers)
Exclusion Criteria:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
- Metastatic disease
- Presence of inflammatory bowel disease and/or ileus
- Known hypersensitivity reaction to any of the components of study treatments.
- Pregnancy (absence to be confirmed by β-hCG test) or breast-feeding period
- Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia (for men: QTc ≥450 msec, for women: QTc ≥470 msec)
- Previous malignancy in the last 5 years except curative treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
- Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
- History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v4.03.
- Any significant disease which, in the investigator's opinion, would exclude the patient from the study.
- Patient with a DPD deficiency or UGT1A1 homozygous 7/7; the test should be done for all patients before 5-FU administration, according to ANSM communication regarding recommendation about high risk of no testing DPD in patient before 5-FU administration; (Appendices 8 to 11).
- Patients already included in another therapeutic trial involving an experimental drug
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02967289
Contacts
| Contact: Beata JUZYNA | 0033.1.71.93.63.66 | b-juzyna@unicancer.fr | |
| Contact: Veronica PEZZELLA | v-pezzella@unicancer.fr |
Locations
Show 17 study locations
Sponsors and Collaborators
UNICANCER
Canadian Cancer Trials Group
GONO GROUP
Investigators
| Study Chair: | Jaafar BENNOUNA, Professor | Hôpital FOCH, SURESNES | |
| Study Chair: | Julien TAIEB, Professor | Hôpital Européen Georges-Pompidou, PARIS | |
| Study Chair: | Thierry ANDRE, Professor | AP-HP Hôpital Saint-Antoine, PARIS |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | UNICANCER |
| ClinicalTrials.gov Identifier: | NCT02967289 |
| Other Study ID Numbers: |
UC-0110/1609_PRODIGE52/UCGI29 2016-001491-29 ( EudraCT Number ) |
| First Posted: | November 18, 2016 Key Record Dates |
| Last Update Posted: | August 3, 2022 |
| Last Verified: | August 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
| Time Frame: | The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement. |
| Access Criteria: | Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data. |
| URL: | https://www.google.com/maps/d/u/2/viewer?mid=1z7kLXwQjEMgrBzzyYNwijVdgXMIXqVIy&ll=35.52580937282327%2C-54.931599049999996&z=3 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by UNICANCER:
|
colon cancer stage 3 high-risk |
mFolfirinox mFolfox6 adjuvant |
Additional relevant MeSH terms:
|
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases |
Colonic Diseases Intestinal Diseases Irinotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |